About SOV Therapeutics
SOV Therapeutics, Inc. (SOV) is a privately held clinical stage biotechnology company focused on improving the utility of known efficacious pharmaceutical compounds by employing innovative drug delivery technologies. These technologies are designed to avoid the negative effects of first-pass metabolism by the liver. SOV-developed products seek to deliver medications with reduced side effects and improved patient outcomes compared to existing marketed products.
In-vitro and in-vivo "proof of concept" studies of SOV’s proprietary delivery technology in beagle dogs demonstrated enhanced bioavailability of testosterone relative to formulation of the marketed product "Andriol® Testocaps®".
Phase 1 & 2 Clinical Program
SOV has completed Phase I & II ( single dose, dose escalation, food effect and steady-state repeat-dose PK) clinical studies in
hypogonadal men with the final formulation. The drug product is well tolerated with no adverse safety findings. SOV Therapeutics is willing to review data with potential partners. Plans for start of Phase III are under development and will be submitted to FDA for their feedback and approval. FDA has approved our Phase II study design for adolescent boys and clinical trial will be starting later this year.
Advantages of SOV Product
Easy-to-swallow capsule to be taken twice daily with a low or a normal fat meal, which we believe will be easier and safer to use than testosterone-replacement therapies currently on the market.